Franco-Quebecois Forum for Health Innovation (FFQIS): successful second edition strengthens internat

With a focus on medical imaging, digital health, biomaterials and biomechanics, the event, promoting knowledge sharing and B2B meetings, took place on May 15 and 16 in Paris   Paris and Montreal, May 17, 2018 – Medicen Paris Region, the French Alliance for Life Sciences and Health (Alliance française pour les sciences de la vie et de la santé - Aviesan), MEDTEQ and Polytechnique Montréal and TransMedTech, alongside several French and Quebecois partners...

READ MORE...

Discngine receives €600,000 ($743K) from Bpifrance

Funding will enable company to conduct research program on collaborative large scale three-dimensional data management for biomolecules Paris, France, May 14, 2018 – Discngine, a software company specialized in developing applications for life sciences research, today announces that it has received funding of €600,000 ($743K) from Bpifrance. This figure comprises an interest-free loan of €300,000 and an ‘innovation loan’ of €300,000. The objective is to c...

READ MORE...

Medtech Boston: Bpifrance, French Tech Hub and Medicen Paris Region unveil the eight selected startu

Paris, France, April 16, 2018 – Medtech Boston is a program for medtech and e-health companies (medical devices, connected devices, monitoring or diagnostics products). Created by French Tech Hub, Medicen Paris Region, Bpifrance and Mednest, this program aims to help innovative companies develop their products in the US market. The eight selected companies of this third edition were announced today on the occasion of the preparatory bootcamp. They will attend an intensive week during ...

READ MORE...

The seven French health competitiveness clusters create a network

To increase the visibility of their 1,300 members, including 1,000 SMEs, and promote their economic value, the health clusters will speak with one voice Paris, April 11, 2018 - The seven French health competitiveness clusters - Alsace Biovalley, Atlanpole Biotherapies, Cancer-Bio-Santé, Eurobiomed, Lyonbiopole, Medicen Paris Region and Nutrition-Health-Longevity - announce today that they are stenghtening their collaboration to highlight the results of the activities they have und...

READ MORE...

Paris Region Entreprises, in partnership with GIP Resah and Medicen Paris Region, launches call for

Paris, March 28, 2018 - This call for projects is part of the European project inDemand, which aims to create a new model where institutional health organizations and companies join forces to develop innovative digital solutions with financial support from regional public funds. The aim of the inDemand project is to solve challenges identified by healthcare professionals (doctors, nurses, service managers, etc). Taking these challenges into account then leads to the financing of inn...

READ MORE...

NovAliX enters into cooperation agreement with  Max-Planck spin-off

With exclusive rights to sell purified human 20S proteasome, a promising target for hematological malignancy treatment and cancer drug development, NovAliX will also provide structural biology analysis by X-ray crystallography of the protein complex Illkirch, France, March 26, 2018 – NovAliX, a drug discovery-focused Contract Research Organization (CRO) today announces that it has signed a cooperation agreement with German-based ProteoPlex GmbH, a spin-off company of the Max-Planck...

READ MORE...

Medicen Paris Region and its partners organize second edition of Franco-Québécois Forum for Health

With a focus on medical imaging, digital health, biomaterials and biomechanics, the event will promote collaboration and B2B meetings on May 15 and 16 in Paris   Paris and Montréal, March 21, 2018 – Medicen Paris Region, the leading health competitiveness cluster in Europe, today announces an event organized to strengthen Franco-Quebecois collaborations in the medical technology industry. This second edition of the Franco-Québécois Forum for Health ...

READ MORE...

Domain Therapeutics’ innovative business model gains validation through Prexton Therapeutics\' acq

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech Strasbourg, France, March 20, 2018 – Domain Therapeutics is pleased to congratulate its partner company Prexton Therapeutics (Prexton) on its acquisition by H. Lundbeck A/S (Lundbeck). Prexton’s drug candidate, Foliglurax, is currently in clinical Phase II for symptomatic treatment of OFF-time and dyskinesia (...

READ MORE...

undbeck to acquire Prexton Therapeutics in a deal valued at up to €905 million

Lundbeck will make an upfront payment of €100 million plus up to €805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment, which entered clinical phase II testing in Parkinson’s disease in July 2017 There remains a large unmet need for effective treatments for Parkinson’s patients to sustain the utility of dopaminergic therapies and to address motor and non-motor symptoms Oss, the Netherlands, March 16, 2018 - H. ...

READ MORE...

Sebia launches new-generation serum free light chain (sFLC) assays for multiple myeloma testing  

New test assays improve analytics and clinical coherence for the diagnosis and monitoring of multiple myeloma   Paris, France, March 14, 2018 – Sebia, a world leader in multiple myeloma diagnostics and monitoring, announces today the launch of two new-generation serum free light chain (sFLC) assays for multiple myeloma testing: sebia FLC Kappa and sebia FLC Lambda. The two new assays aim to provide more consistent results by overcoming the challenges in analytical performance a...

READ MORE...